226 related articles for article (PubMed ID: 29751678)
1. (-)-Epigallocatechin 3-Gallate Synthetic Analogues Inhibit Fatty Acid Synthase and Show Anticancer Activity in Triple Negative Breast Cancer.
Crous-Masó J; Palomeras S; Relat J; Camó C; Martínez-Garza Ú; Planas M; Feliu L; Puig T
Molecules; 2018 May; 23(5):. PubMed ID: 29751678
[TBL] [Abstract][Full Text] [Related]
2. EGCG-Derivative G28 Shows High Efficacy Inhibiting the Mammosphere-Forming Capacity of Sensitive and Resistant TNBC Models.
Giró-Perafita A; Rabionet M; Planas M; Feliu L; Ciurana J; Ruiz-Martínez S; Puig T
Molecules; 2019 Mar; 24(6):. PubMed ID: 30875891
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer.
Giró-Perafita A; Palomeras S; Lum DH; Blancafort A; Viñas G; Oliveras G; Pérez-Bueno F; Sarrats A; Welm AL; Puig T
Clin Cancer Res; 2016 Sep; 22(18):4687-97. PubMed ID: 27106068
[TBL] [Abstract][Full Text] [Related]
4. Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells.
Brusselmans K; De Schrijver E; Heyns W; Verhoeven G; Swinnen JV
Int J Cancer; 2003 Oct; 106(6):856-62. PubMed ID: 12918062
[TBL] [Abstract][Full Text] [Related]
5. Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75.
Puig T; Vázquez-Martín A; Relat J; Pétriz J; Menéndez JA; Porta R; Casals G; Marrero PF; Haro D; Brunet J; Colomer R
Breast Cancer Res Treat; 2008 Jun; 109(3):471-9. PubMed ID: 17902053
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?
Lupu R; Menendez JA
Curr Pharm Biotechnol; 2006 Dec; 7(6):483-93. PubMed ID: 17168665
[TBL] [Abstract][Full Text] [Related]
7. Different fatty acid metabolism effects of (-)-epigallocatechin-3-gallate and C75 in adenocarcinoma lung cancer.
Relat J; Blancafort A; Oliveras G; Cufí S; Haro D; Marrero PF; Puig T
BMC Cancer; 2012 Jul; 12():280. PubMed ID: 22769244
[TBL] [Abstract][Full Text] [Related]
8. Recent Advances in the Development of Fatty Acid Synthase Inhibitors as Anticancer Agents.
Singh S; Karthikeyan C; Moorthy NSHN
Mini Rev Med Chem; 2020; 20(18):1820-1837. PubMed ID: 32781957
[TBL] [Abstract][Full Text] [Related]
9. Novel Inhibitors of Fatty Acid Synthase with Anticancer Activity.
Puig T; Turrado C; Benhamú B; Aguilar H; Relat J; Ortega-Gutiérrez S; Casals G; Marrero PF; Urruticoechea A; Haro D; López-Rodríguez ML; Colomer R
Clin Cancer Res; 2009 Dec; 15(24):7608-7615. PubMed ID: 20008854
[TBL] [Abstract][Full Text] [Related]
10. Fatty acid synthase regulates the chemosensitivity of breast cancer cells to cisplatin-induced apoptosis.
Al-Bahlani S; Al-Lawati H; Al-Adawi M; Al-Abri N; Al-Dhahli B; Al-Adawi K
Apoptosis; 2017 Jun; 22(6):865-876. PubMed ID: 28386750
[TBL] [Abstract][Full Text] [Related]
11. Green tea catechin inhibits fatty acid synthase without stimulating carnitine palmitoyltransferase-1 or inducing weight loss in experimental animals.
Puig T; Relat J; Marrero PF; Haro D; Brunet J; Colomer R
Anticancer Res; 2008; 28(6A):3671-6. PubMed ID: 19189648
[TBL] [Abstract][Full Text] [Related]
12. Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.
Blancafort A; Giró-Perafita A; Oliveras G; Palomeras S; Turrado C; Campuzano Ò; Carrión-Salip D; Massaguer A; Brugada R; Palafox M; Gómez-Miragaya J; González-Suárez E; Puig T
PLoS One; 2015; 10(6):e0131241. PubMed ID: 26107737
[TBL] [Abstract][Full Text] [Related]
13. Enhanced antitumor activities of (-)-epigallocatechin-3-O-gallate fatty acid monoester derivatives in vitro and in vivo.
Matsumura K; Kaihatsu K; Mori S; Cho HH; Kato N; Hyon SH
Biochem Biophys Res Commun; 2008 Dec; 377(4):1118-22. PubMed ID: 18983978
[TBL] [Abstract][Full Text] [Related]
14. Novel anti-fatty acid synthase compounds with anti-cancer activity in HER2+ breast cancer.
Oliveras G; Blancafort A; Urruticoechea A; Campuzano O; Gómez-Cabello D; Brugada R; López-Rodríguez ML; Colomer R; Puig T
Ann N Y Acad Sci; 2010 Oct; 1210():86-92. PubMed ID: 20973802
[TBL] [Abstract][Full Text] [Related]
15. Shining a Light on the Effects of the Combination of (-)-Epigallocatechin-3-gallate and Tapentadol on the Growth of Human Triple-negative Breast Cancer Cells.
Bimonte S; Cascella M; Barbieri A; Arra C; Cuomo A
In Vivo; 2019; 33(5):1463-1468. PubMed ID: 31471393
[TBL] [Abstract][Full Text] [Related]
16. EGCG Inhibits Adipose-Derived Mesenchymal Stem Cells Differentiation into Adipocytes and Prevents a STAT3-Mediated Paracrine Oncogenic Control of Triple-Negative Breast Cancer Cell Invasive Phenotype.
Gonzalez Suarez N; Rodriguez Torres S; Ouanouki A; El Cheikh-Hussein L; Annabi B
Molecules; 2021 Mar; 26(6):. PubMed ID: 33801973
[TBL] [Abstract][Full Text] [Related]
17. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling.
Pan MH; Lin CC; Lin JK; Chen WJ
J Agric Food Chem; 2007 Jun; 55(13):5030-7. PubMed ID: 17539658
[TBL] [Abstract][Full Text] [Related]
18. A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent.
Landis-Piwowar KR; Huo C; Chen D; Milacic V; Shi G; Chan TH; Dou QP
Cancer Res; 2007 May; 67(9):4303-10. PubMed ID: 17483343
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of emodin on fatty acid synthase, colon cancer proliferation and apoptosis.
Lee KH; Lee MS; Cha EY; Sul JY; Lee JS; Kim JS; Park JB; Kim JY
Mol Med Rep; 2017 Apr; 15(4):2163-2173. PubMed ID: 28260110
[TBL] [Abstract][Full Text] [Related]
20. Analyzing effects of extra-virgin olive oil polyphenols on breast cancer-associated fatty acid synthase protein expression using reverse-phase protein microarrays.
Menendez JA; Vazquez-Martin A; Oliveras-Ferraros C; Garcia-Villalba R; Carrasco-Pancorbo A; Fernandez-Gutierrez A; Segura-Carretero A
Int J Mol Med; 2008 Oct; 22(4):433-9. PubMed ID: 18813848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
